Samina Bari is a Biotech Executive and Strategic Advisor with a distinguished track record of value creation for shareholders through notable acquisitions within the biopharmaceutical industry. Samina is a valued partner to CEOs and boards and advises companies at various stages of transition, whether private or IPO, early-stage public, or from development stage to commercialization. She uses her expertise in company transformation and exit preparation by reframing investment theses to influence value perception resulting in high-value acquisitions.
Samina has 30+ years of experience and success in delivering outcome- and analytics-driven results in complex and competitive businesses. She has strong operational experience, a governance/compliance mindset, fiduciary stewardship, and DEI leadership. She is a seasoned company officer and Executive Team member at NASDAQ: AIMT, NASDAQ: AXON, and NASDAQ: PCYC.
Samina has 30+ years of experience and success in delivering outcome- and analytics-driven results in complex and competitive businesses. She has strong operational experience, a governance/compliance mindset, fiduciary stewardship, and DEI leadership. She is a seasoned company officer and Executive Team member at NASDAQ: AIMT, NASDAQ: AXON, and NASDAQ: PCYC.
Activity